Original Article

Maternal and Infant Outcomes in a Subset of Patients with Sickle Cell Disease in South Carolina

Authors: Christina M. Abrams, MD, Caroline B. Foster, PhD, Natalia Davila, DNP, APRN, CPNP-PC, Marcelaine Reneau, PhD, FNP-BC, Earleisha Felder, PA-C, Martina Mueller, PhD, Caroline Davila, MHA

Abstract

Objectives: Sickle cell disease (SCD), which disproportionately affects minorities, increases complications during pregnancy. Severe maternal mortality is increased in women with SCD, including morbidity related to the disease and other nondisease-related complications. It also can have devastating complications for fetuses, with increases in premature birth and low birth weight. This study aimed to describe the characteristics of women with SCD in South Carolina, with a specific focus on fetal and maternal outcomes and complications. The secondary aim of this study was to identify the effect of maternal characteristics on birth outcomes, including social determinants of health.

Methods: A secondary analysis of women from a single institution, the Medical University of South Carolina, which was part of the registry from the multi-institutional Sickle Cell Disease Implementation Consortium, was conducted. Patient demographics, self-reported pregnancy history, hydroxyurea use, and maternal and fetal outcomes were collected from patient-reported survey data. In addition, the number of vaso-occlusive episodes surrounding their pregnancies was collected for analysis.

Results: Fifty-nine percent (116/195) of the female participants reported ever being pregnant. Seventy-two percent had live births, 15.8% had miscarriages, 1.8% had stillbirths, and 6.1% had an abortion. The mean age was 22.3 ± 4 years, with no difference in markers of severity between the groups. Most women were HbSS genotype with high rates of pain in the last year. No difference was found in age, education, employment, or income between these groups of women. Women in the nonlive birth cohort had higher body weights (78.7 versus 72.1 kg, P = 0.045). The Distressed Community Index was used as a marker for social determinants of health and was similar between the two groups, with a majority of both cohorts (61.7% and 52%) living in “at risk” and “distressed” communities. Complications related to SCD were high, including 43% of women experiencing pain during pregnancy, 5.2% developing acute chest syndrome, and 22.4% requiring transfusion. An additional 11% experienced preeclampsia. Unfavorable infant outcomes included 49% of the infants being premature and 40% having babies weighing less than 5.5 lb at birth.

Conclusions: High rates of complications to both mother and infant were found in the women with SCD. Although few statistically significant predictors were found, by identifying and addressing specific needs of pregnant women with SCD, we can work toward reducing fetal and maternal mortality in an already vulnerable population.
Posted in: Pregnancy35

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Kavanagh PL, Fasipe TA, Wun T. Sickle cell disease: a review. JAMA 2022;328:57-68.
 
2. Centers for Disease Control and Prevention; National Center on Birth Defects and Developmental Disabilities. Data and statistics on sickle cell disease. https://www.cdc.gov/sickle-cell/data/?CDC_AAref_Val=https://www.cdc.gov/ncbddd/sicklecell/data.html. Updated May 2, 2022. Accessed February 1, 2023.
 
3. South Carolina Sickle Cell Disease Advocacy Team. A call to action: South Carolina sickle cell disease state plan 2019-2022. https://scdhec.gov/sites/default/files/Library/CR-012241.pdf. Updated October 2018. Accessed February 1, 2023.
 
4. Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med 2010;38(4 Suppl):S512-521.
 
5. Conran N, Franco-Penteado CF, Costa FF. Newer aspects of the pathophysiology of sickle cell disease vaso-occlusion. Hemoglobin 2009;33:1-16.
 
6. Kato GJ, Hebbel RP, Steinberg MH, et al. Vasculopathy in sickle cell disease: biology, pathophysiology, genetics, translational medicine, and new research directions. Am J Hematol 2009;84:618-625.
 
7. Noguchi CT, Schechter AN, Rodgers GP. Sickle cell disease pathophysiology. Baillieres Clin Haematol 1993;6:57-91.
 
8. Steinberg MH. Management of sickle cell disease. N Engl J Med 1999;340:1021-1030.
 
9. Bornstein E, Eliner Y, Chervenak FA, et al. Racial disparity in pregnancy risks and complications in the US: temporal changes during 2007-2018. J Clin Med 2020;9:1414.
 
10. Boghossian NS, Greenberg LT, Saade GR, et al. Association of sickle cell disease with racial disparities and severe maternal morbidities in Black individuals. JAMA Pediatr 2023;177: 808-817.
 
11. Hung P, Liu J, Norregaard C, et al. Analysis of residential segregation and racial and ethnic disparities in severe maternal morbidity before and during the COVID-19 pandemic. JAMA Netw Open 2022;5:e2237711.
 
12. Alayed N, Kezouh A, Oddy L,etal. Sickle cell disease and pregnancy outcomes: population-based study on 8.8 million births. J Perinat Med 2014;42:487-492.
 
13. DeBaun MR, Ghafuri DL, Rodeghier M, et al. Decreased median survival of adults with sickle cell disease after adjusting for left truncation bias: a pooled analysis. Blood 2019;133: 615-617.
 
14. Newman T, Yang J, Kangho S, et al. Trends of disease modifying treatment use in sickle cell disease: retrospective analysis of claims data, 2014-2020. Blood 2022;140(Suppl 1): 1389-1390. 
 
15. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994;330:1639-1644.
 
16. Quinn CT, Rogers ZR, McCavit TL, et al. Improved survival of children and adolescents with sickle cell disease. Blood 2010;115:3447-3452.
 
17. Adesina OO, Brunson A, Fisch SC, et al. Pregnancy outcomes in women with sickle cell disease in California. Am J Hematol 2023;98:440-448.
 
18. Early ML, Eke AC, Gemmill A, et al. Severe maternal morbidity and mortality in sickle cell disease in the National Inpatient Sample, 2012-2018. JAMA Netw Open 2023;6:e2254552.
 
19. Fashakin V, Weber JM, Truong T, et al. Sickle cell disease and the incidence and etiology of preterm birth. Am J Obstet Gynecol MFM 2022;4:100723.
 
20. Malinowski AK, Kuo KHM, Tomlinson GA, et al. Distinct maternal and fetal pregnancy outcomes in women with sickle cell disease can be predicted using routine clinical and laboratory data. Br J Haematol 2021;194:1063-1073.
 
21. Noubouossie D, Key NS. Sickle cell disease and venous thromboembolism in pregnancy and the puerperium. Thromb Res 2015;135(Suppl 1):S46-S48.
 
22. Seaman CD, Yabes J,Li J,et al. Venous thromboembolism in pregnant women with sickle cell disease: a retrospective database analysis. Thromb Res 2014;134:1249-1252.
 
23. Sharif J, Byrd L, Stevenson K, etal. Transfusion for sickle cell disease in pregnancy: a singlecentre survey. Transfus Med 2018;28:231-235.
 
24. Smith-Whitley K. Complications in pregnant women with sickle cell disease.Hematology Am Soc Hematol Educ Program 2019;2019:359-366.
 
25. Sun PM, Wilburn W, Raynor BD, et al. Sickle cell disease in pregnancy: twenty years of experience at Grady Memorial Hospital, Atlanta, Georgia. Am J Obstet Gynecol 2001;184: 1127-1130.
 
26. Boafor TK, Olayemi E, Galadanci N, et al. Pregnancy outcomes in women with sickle-cell disease in low and high income countries: a systematic review and meta-analysis. BJOG 2016; 123:691-698. 
 
27. Oteng-Ntim E, Meeks D, Seed PT, et al. Adverse maternal and perinatal outcomes in pregnant women with sickle cell disease: systematic review and meta-analysis. Blood 2015;125: 3316-3325.
 
28. Glassberg JA, Linton EA, Burson K, et al. Publication of data collection forms from NHLBI funded Sickle Cell Disease Implementation Consortium (SCDIC) registry. Orphanet J Rare Dis 2020;15:178. .
 
29. Distressed Community Index Report. https://eig.org/distressed-communities/?geo=states&lat=38.55&lon=-96.42&z=3.62. Accessed August 3, 2023.
 
30. Kroner BL, Hankins JS, Pugh N, et al. Sickle Cell Disease Implementation Consortium. Pregnancy outcomes with hydroxyurea use in women with sickle cell disease. Am J Hematol 2022;97:603-612. .
 
31. Ibemere SO, Oyedeji CI, Preiss L, et al. Characterising the prevalence of overweight and obese status among adults with sickle cell disease. Br J Haematol 2023;200:633-642.
 
32. Hall R, Gardner K, Rees DC, et al.High body mass index in children with sickle cell disease: a retrospective single-centre audit. BMJ Paediatr Open 2018;2:e000302.
 
33. Creanga AA, Catalano PM, Bateman BT. Obesity in pregnancy. NEnglJMed2022;387: 248-259.
 
34. Kanguru L, McCaw-Binns A, Bell J, et al. The burden of obesity in women of reproductive age and in pregnancy in a middle-income setting: a population based study from Jamaica. PLoS One 2017;12:e0188677. 
 
35. Wang E, Glazer KB, Howell EA, et al. Social determinants of pregancy-related mortality and morbidity in the United States: a systematic review. Obstet Gynecol 2020;135:896-915.
 
36. Ally SA, Han J, Sun R, et al. Community-level socioeconomic distress is associated with nutritional status in adults with sickle cell anemia. EJHaem 2023;4:432-436.
 
37. Kuo K, Caughey AB. Contemporary outcomes of sickle cell disease in pregnancy. Am J Obstet Gynecol 2016;215:505e1-505e5.
 
38. Piel FB, Steinberg MH, Rees DC. Sickle cell disease. N Engl J Med 2017;376:1561-1573.
 
39. Habibi A, Cannas G, Bartolucci P,et al. Outcomes of pregnancy in sickle cell disease patients: results from the Prospective ESCORT-HU Cohort Study. Biomedicines 2023;11:597.
 
40. Institute for Families in Society. SC Birth Outcomes Initiative Interactive Dashboard. https://boi.ifsreports.com/. Accessed August 7, 2023.